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Introduction {#sec005}
============

Thyroidectomy is a widely used and relatively safe procedure having a major postoperative morbidity of less than 5% for experienced surgeons.\[[@pone.0207088.ref001]\] Major complications include recurrent laryngeal nerve injury, postoperative hemorrhage and hypocalcemia.\[[@pone.0207088.ref002]\] Among these, hypocalcemia is the most common complication, with an incidence of 7--51%.\[[@pone.0207088.ref003]--[@pone.0207088.ref005]\] The quality of life is decreased in patients suffering from postoperative hypocalcemia, particularly in those suffering from clinical hypocalcemia. Moreover, prolonged or long-term calcium supplementation might be necessary for transient or permanent hypocalcemia. Surgical trauma, devascularization, extent of surgery, and incidental parathyroidectomy (IP) have been found to affect postoperative hypocalcemia.\[[@pone.0207088.ref002], [@pone.0207088.ref004], [@pone.0207088.ref006]\]

IP has been defined as parathyroid tissue found in a postoperative specimen and occurs in 6--28% of thyroidectomy.\[[@pone.0207088.ref003]--[@pone.0207088.ref005]\] Even with careful dissection and sufficient anatomical knowledge, the identification and in situ preservation of parathyroid tissue remains challenging. There are several anatomic variants of parathyroid glands, particularly of the inferior parathyroid.\[[@pone.0207088.ref007]\] Parathyroid glands are usually surrounded by fat and connective tissue, and this can be excised as thyroid, lymph or fat tissue. Some studies have shown that pathology type, procedure extent, reoperation and central neck dissection are risk factors of IP in thyroidectomy.\[[@pone.0207088.ref004], [@pone.0207088.ref008]\] However, these relationships have not been found in all studies.\[[@pone.0207088.ref009]--[@pone.0207088.ref011]\]

The influence of IP on postoperative hypocalcemia remains controversial. Some studies have found an increased risk of postoperative hypocalcemia in IP patients, particularly of biochemical hypocalcemia.\[[@pone.0207088.ref004], [@pone.0207088.ref011], [@pone.0207088.ref012]\] However, other studies have found no significant relationship between IP and postoperative hypocalcemia.\[[@pone.0207088.ref013]--[@pone.0207088.ref015]\] This difference might be caused by the use of different definitions for postoperative hypocalcemia and for biochemical or clinical hypocalcemia. Further attention has been paid to permanent hypocalcemia. Most researchers have found only negative results, and this might be caused by the relatively low incidence of permanent hypocalcemia and insufficient sample sizes.\[[@pone.0207088.ref016]--[@pone.0207088.ref018]\] Nevertheless, some researchers have found a significant effect of IP on permanent hypocalcemia.\[[@pone.0207088.ref004], [@pone.0207088.ref005]\] Several confounding factors were involved in these results, such as the definition of permanent hypocalcemia, procedure extent, and pathology type. Based on these considerations, we conducted a systematic review and integrated related data to identify the risk factors of IP and the effect of IP on postoperative hypocalcemia in thyroidectomy. Further subgroup analyses were also performed to assess related factors that were mentioned in previous studies.

Materials and methods {#sec006}
=====================

Search strategy and selection criteria {#sec007}
--------------------------------------

We performed a comprehensive literature search of MEDLINE (PubMed), BIOSIS Previews (ISI Web of Knowledge) and the Cochrane library from January 1990 to September 2017. We also manually added relevant articles by reviewing the references. Search terms included: \"incidental parathyroidectomy\" or \"unintentional parathyroidectomy\" or \"inadvertent parathyroidectomy\", \"thyroidectomy\" or \"thyroid surgery\" or \"thyroid resection\", and \"hypocalcemia\" or \"hypocalcemia\" or \"hypoparathyroidism\". The studies included were confined to randomized controlled trials and case control studies and cohort studies with convertible effects data of IP in thyroidectomy. Studies that did not define postoperative hypocalcemia or permanent hypocalcemia were excluded. For postoperative hypocalcemia, data that were collected with a clear distinction between biochemical and clinical hypocalcemia were included. Most of the included papers only defined hypocalcemia and permanent hypocalcemia and did not define transient hypocalcemia. For this reason, transient hypocalcemia is not discussed in this study. We defined temporary/permanent hypocalcemia as any hypocalcemia occurring after thyroidectomy, regardless of hypocalcemia duration, to ensure that we could present and discuss the data appropriately. For permanent hypocalcemia, we only included data for which permanent hypocalcemia was defined as lasting more than 6 months, consistent with relevant studies.\[[@pone.0207088.ref004], [@pone.0207088.ref018]\] If several papers extracted data from the same population, we only included the most recent. Paper selection involved four steps, including identification, screening, the determination of eligibility and inclusion. For identification, we found papers through searching the databases, and duplicate papers were determined based on title, author and abstract. There was no disagreement in this step. At the screening and eligibility steps, some disagreement existed among us, with Kappa values of 0.8922 and 0.8256.

Data extraction and quality assessment {#sec008}
--------------------------------------

Data were independently extracted by two authors (BL Bai and WZ Chen). Detailed information was recorded on first author, year of publication, location, study type, pathology type, procedure extent, biochemical or clinical hypocalcemia, definition of permanent hypocalcemia, the number and location of parathyroid glands found in the specimen, the number of case and control groups, the event of malignancy, central neck dissection, reoperation, total thyroidectomy, temporary/permanent and permanent hypocalcemia, and Newcastle-Ottawa Scale score (NOS). The Newcastle-Ottawa Scale for Quality was used to assess the included cohort studies, yielding a minimum score of 0 and a maximum score of 9.\[[@pone.0207088.ref019]\] There were three sections in the NOS; selection, comparability and outcome. We modified some features in the sections relating to comparability and outcome. For the section on comparability, one score was used for study controls for basic characters, such as age, gender and histopathology. Another score was used for study controls for the additional factor of surgery extent. For the outcome section, one score was used for a study follow-up of more than 6 months. We considered a follow-up in which fewer than 10% of the cohort was lost as small and unlikely to introduce bias.

Statistical methods {#sec009}
-------------------

Meta-analysis was performed under the R environment 3.4.1 in the Meta package 4.8--3.\[[@pone.0207088.ref020]\] In accordance with recommendations of the Cochrane Collaboration, risk ratio (RR), risk difference (RD) and confidence interval (CI) were calculated using the random-effects model using an inverse variance weight to compare the difference.\[[@pone.0207088.ref021]--[@pone.0207088.ref023]\] If zero events happened in both the experimental and control groups, the pooled RD estimates and 95% CIs were applied. Otherwise, RR was applied. RR below one or RD below zero indicates a benefit of the experimental intervention. We estimated 95% CI from the 2.5th and 97.5th percentiles of the posterior distribution and calculated two-sided p values from the posterior distribution. If the 95% CI does not contain the valid value 0 for RD or 1 for RR, the result is considered to represent a significant difference. Publication bias was assessed using funnel plots, Begg's test and Egger's regression asymmetry test.\[[@pone.0207088.ref024]\] The heterogeneity between trials was estimated from the median between-trial variance (τ^2^) observed in the posterior distribution. Meta-regression analysis was conducted to assess the causes of heterogeneity.\[[@pone.0207088.ref025]\]

Results {#sec010}
=======

Description of studies {#sec011}
----------------------

A total of 236 articles were identified through the literature search. After duplicates were removed, 210 articles were included for screening. Among these, 62 eligible full-text articles were selected after carefully checking the titles and abstracts.([Fig 1](#pone.0207088.g001){ref-type="fig"}) However, we excluded 27 of the 62 articles because they contained unconvertible data (4 articles)\[[@pone.0207088.ref026]--[@pone.0207088.ref029]\], lacked hypocalcemia data for the control group (8 articles)\[[@pone.0207088.ref030]--[@pone.0207088.ref037]\], duplicated data derived from same center (6 articles), or did not give a clear definition of hypocalcemia (9 articles)\[[@pone.0207088.ref038]--[@pone.0207088.ref046]\]. Finally, 35 articles were included in the systematic review and meta-analysis.\[[@pone.0207088.ref003]--[@pone.0207088.ref005], [@pone.0207088.ref008]--[@pone.0207088.ref018], [@pone.0207088.ref047]--[@pone.0207088.ref067]\] Details on first author, year of publication, location, study type, pathology, procedure extent, the definition of permanent hypocalcemia and NOS score were recorded. ([Table 1](#pone.0207088.t001){ref-type="table"}) Two prospective cohorts and 33 retrospective cohorts were included in our study. The pathology was divided into benign and malignant cases. Two studies included only benign cases, 7 studies included only malignant cases, and the remaining 26 studies included both benign and malignant cases. The procedures used in the included studies were diverse. Twelve studies focused their discussion on total thyroidectomy. Twenty-three studies defined permanent hypocalcemia as having a duration of more than 6 months. The NOS of the included studies ranged from 6 to 9, suggesting that the studies were of acceptable quality. The main characteristics of the studies that were excluded based on the full-text article assessment are shown in [S1 Table](#pone.0207088.s006){ref-type="supplementary-material"}.

![Flow diagram of the study selection.\
Two authors (BL Bai and WZ Chen) participated separately in the entire study selection process. We identified papers through a database search, and duplicate papers were identified based on title, author and abstract. There was no disagreement at this step. For screening and eligibility, some disagreement occurred, with Kappa values of 0.8922 and 0.8256.](pone.0207088.g001){#pone.0207088.g001}

10.1371/journal.pone.0207088.t001

###### Main characteristic of included studies.

![](pone.0207088.t001){#pone.0207088.t001g}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                   Year   Location         Study type   Pathology            Procedure extent   Biochemical hypocalcemia definition   Clinical hypocalcemia\                         Permanent\                                          Permanent duration   NOS score
                                                                                                                                                              definition                                     measurement                                                              
  ---------------------------------------- ------ ---------------- ------------ -------------------- ------------------ ------------------------------------- ---------------------------------------------- --------------------------------------------------- -------------------- -----------
  Sasson\[[@pone.0207088.ref062]\]         2001   USA              RC           Benign & Malignant   TT, ST, LB         NS                                    Symptom[\*](#t001fn002){ref-type="table-fn"}   Symptom[\*](#t001fn002){ref-type="table-fn"}        12 months            8

  Sakorafas\[[@pone.0207088.ref061]\]      2005   Greece           RC           Benign & Malignant   TT, NT, LB, ST     sCa\<8.0mg/dL                         Symptom[\*](#t001fn002){ref-type="table-fn"}   Symptom[\*](#t001fn002){ref-type="table-fn"}        12 months            7

  Gourgiotis\[[@pone.0207088.ref013]\]     2006   Greece           RC           Benign & Malignant   TT, NT, LB         sCa\<8.0mg/dL                         NS                                             NS                                                  \-                   7

  Abboud\[[@pone.0207088.ref047]\]         2007   Lebanon          RC           Benign & Malignant   TT, NT, LB         sCa\<8.0mg/dL                         Symptom[\*](#t001fn002){ref-type="table-fn"}   NS                                                  \-                   8

  Cavicchi\[[@pone.0207088.ref049]\]       2007   Italy            PC           Benign & Malignant   UT, BT             NS                                    Symptom[\*](#t001fn002){ref-type="table-fn"}   NS                                                  \-                   6

  Irkorucu\[[@pone.0207088.ref051]\]       2007   Turkey           RC           Benign & Malignant   TT, NT, LB, ST     NS                                    Symptom[\*](#t001fn002){ref-type="table-fn"}   NS                                                  \-                   7

  Page\[[@pone.0207088.ref014]\]           2007   France           RC           Benign only          TT                 sCa\<8.0mg/dL                         SNS                                            sCa\<8.0mg/dL                                       24 months            7

  Sippel\[[@pone.0207088.ref064]\]         2007   USA              RC           Benign & Malignant   TT, CT, ST, LB     sCa\<8.0mg/dL                         Symptom[\*](#t001fn002){ref-type="table-fn"}   NS                                                  \-                   7

  Manouras\[[@pone.0207088.ref054]\]       2008   Greece           RC           Benign & Malignant   TT                 sCa\<8.5mg/dL                         NS                                             NS                                                  \-                   9

  Erbil\[[@pone.0207088.ref050]\]          2009   Turkey           RC           Benign only          TT, NT             sCa\<8.0mg/dL                         NS                                             NS                                                  \-                   8

  Rajinikanth\[[@pone.0207088.ref060]\]    2009   India            RC           Benign & Malignant   TT, CT             sCa\<8.0mg/dL                         NS                                             Medication[^\#^](#t001fn003){ref-type="table-fn"}   6 months             7

  Sorgato\[[@pone.0207088.ref008]\]        2009   Italy            RC           Benign & Malignant   TT, CT, ST, LB     sCa\<8.4mg/dL                         NS                                             Medication[^\#^](#t001fn003){ref-type="table-fn"}   12 months            8

  Turanli\[[@pone.0207088.ref066]\]        2009   Turkey           RC           Malignant only       TT, ST, CT         NS                                    NS                                             Medication[^\#^](#t001fn003){ref-type="table-fn"}   6 months             6

  Ondik\[[@pone.0207088.ref056]\]          2010   USA              RC           Malignant only       CT                 NS                                    Symptom[\*](#t001fn002){ref-type="table-fn"}   Medication[^\#^](#t001fn003){ref-type="table-fn"}   6 months             8

  Spiliotis\[[@pone.0207088.ref003]\]      2010   Greece           RC           Benign & Malignant   TT, ST             sCa\<8.0mg/dL                         NS                                             NS                                                  \-                   7

  Youssef\[[@pone.0207088.ref009]\]        2010   Egypt            RC           Benign & Malignant   UT, BT             sCa\<8.0mg/dL                         Symptom[\*](#t001fn002){ref-type="table-fn"}   NS                                                  \-                   8

  Khairy\[[@pone.0207088.ref010]\]         2011   Saudi Arabia     RC           Benign & Malignant   TT, CT, ST, LB     sCa\<8.0mg/dL                         NS                                             sCa\<8.0mg/dL                                       6 months             8

  Qasaimeh\[[@pone.0207088.ref059]\]       2011   Jordan           RC           Benign & Malignant   TT, ST, LB         sCa\<8.0mg/dL                         NS                                             Medication[^\#^](#t001fn003){ref-type="table-fn"}   6 months             8

  Kalyoncu\[[@pone.0207088.ref052]\]       2013   Turkey           RC           Benign & Malignant   TT, NT, ST         sCa\<8.0mg/dL                         NS                                             Medication[^\#^](#t001fn003){ref-type="table-fn"}   6 months             6

  Nair\[[@pone.0207088.ref055]\]           2013   India            RC           Benign & Malignant   TT                 sCa\<8.0mg/dL                         NS                                             Medication[^\#^](#t001fn003){ref-type="table-fn"}   6 months             7

  Paek\[[@pone.0207088.ref012]\]           2013   Korea            RC           Malignant only       TT                 NS                                    Symptom[\*](#t001fn002){ref-type="table-fn"}   Medication[^\#^](#t001fn003){ref-type="table-fn"}   12 months            7

  Sheahan\[[@pone.0207088.ref063]\]        2013   Ireland          PC           Benign & Malignant   TT                 sCa\<8.0mg/dL                         Symptom[\*](#t001fn002){ref-type="table-fn"}   Medication[^\#^](#t001fn003){ref-type="table-fn"}   6 months             7

  Del Rio\[[@pone.0207088.ref016]\]        2014   Italy            RC           Benign & Malignant   TT                 NS                                    NS                                             Medication[^\#^](#t001fn003){ref-type="table-fn"}   12 months            6

  Pergel\[[@pone.0207088.ref058]\]         2014   Turkey           RC           Benign & Malignant   TT                 NS                                    NS                                             sCa\<8.0mg/dL                                       6 months             7

  Prazenica\[[@pone.0207088.ref017]\]      2014   Czech Republic   RC           Benign & Malignant   TT, CT, LB         sCa\<8.0mg/dL                         NS                                             Medication[^\#^](#t001fn003){ref-type="table-fn"}   12 months            8

  Song\[[@pone.0207088.ref065]\]           2014   Korea            RC           Malignant only       TT                 sCa\<8.0mg/dL                         NS                                             Medication[^\#^](#t001fn003){ref-type="table-fn"}   6 months             9

  Lee\[[@pone.0207088.ref053]\]            2015   Korea            RC           Malignant only       TT                 sCa\<8.0mg/dL                         Symptom[\*](#t001fn002){ref-type="table-fn"}   NS                                                  \-                   6

  Wang\[[@pone.0207088.ref067]\]           2015   China            RC           Benign & Malignant   TT                 sCa\<8.8mg/dL                         NS                                             Medication[^\#^](#t001fn003){ref-type="table-fn"}   12 months            6

  Applewhite\[[@pone.0207088.ref048]\]     2016   USA              CC           Benign & Malignant   TT                 sCa\<8.2mg/dL                         Symptom[\*](#t001fn002){ref-type="table-fn"}   NS                                                  \-                   9

  Manatakis\[[@pone.0207088.ref011]\]      2016   Greece           RC           Benign & Malignant   TT                 sCa\<8.0mg/dL                         Symptom[\*](#t001fn002){ref-type="table-fn"}   Medication[^\#^](#t001fn003){ref-type="table-fn"}   6 months             9

  Ozemir\[[@pone.0207088.ref057]\]         2016   Turkey           RC           Benign & Malignant   TT, CT, LB         sCa\<8.5mg/dL                         NS                                             Medication[^\#^](#t001fn003){ref-type="table-fn"}   12 months            6

  Zhou\[[@pone.0207088.ref018]\]           2016   USA              RC           Benign & Malignant   TT, CT, LB         NS                                    NS                                             Medication[^\#^](#t001fn003){ref-type="table-fn"}   6 months             8

  Du\[[@pone.0207088.ref015]\]             2017   China            RC           Malignant only       TT+CND             NS                                    Symptom[\*](#t001fn002){ref-type="table-fn"}   NS                                                  \-                   8

  Lin\[[@pone.0207088.ref004]\]            2017   Taiwan           RC           Benign & Malignant   TT, ST, LB         sCa\<8.0mg/dL                         NS                                             Medication[^\#^](#t001fn003){ref-type="table-fn"}   6 months             8

  Sitges-Serra\[[@pone.0207088.ref005]\]   2017   Spain            PC           Malignant only       TT+CND             sCa\<8.0mg/dL                         NS                                             Medication[^\#^](#t001fn003){ref-type="table-fn"}   12 months            9
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviation: RC, retrospective cohort; PC prospective cohort; TT total thyroidectomy; ST subtotal thyroidectomy; CT completion thyroidectomy; LB lobectomy; NT near-total thyroidectomy; CND central neck dissection; UT unilateral thyroidectomy; BT bilateral thyroidectomy; NOS, Newcastle-Ottawa Scale; sCa serum calcium level; PTH

\* Symptom: hypocalcemic Symptom\* including paraesthesia, muscle cramping, perioral numbness or tingling.

^\#^ Medication: medication requirement of calcium and/or vitamin D.

The distribution of IP among the different high-risk groups is shown in [Table 2](#pone.0207088.t002){ref-type="table"}. Data regarding malignancy were available in 18 studies, data on central neck dissection were available in 12 studies, data on reoperation were available in 4 studies, and data on total thyroidectomy were available in 12 studies. In total, 2033 IP relating to 16423 cases were included in our analysis, with an average incidence of 12.4%. ([S2 Table](#pone.0207088.s007){ref-type="supplementary-material"}) Regarding temporary/permanent postoperative hypocalcemia, data on biochemical hypocalcemia were available in 22 studies, and data on clinical hypocalcemia were available in 14 studies. Among these studies, 8 exhibited both biochemical and clinical hypocalcemia.

10.1371/journal.pone.0207088.t002

###### The distribution of IP risk factors.

![](pone.0207088.t002){#pone.0207088.t002g}

  Author                                  Year   Case, n   Malignancy, n   Central neck dissection, n   Reoperation, n   Total thyroidectomy, n                         
  --------------------------------------- ------ --------- --------------- ---------------------------- ---------------- ------------------------ ----- ---- ----- ---- -----
  Sasson\[[@pone.0207088.ref062]\]        2001   21        120             11                           62               5                        10    \-   \-    12   57
  Sakorafas\[[@pone.0207088.ref061]\]     2005   28        130             4                            40               \-                       \-    \-   \-    \-   \-
  Gourgiotis\[[@pone.0207088.ref013]\]    2006   68        247             10                           65               \-                       \-    \-   \-    \-   \-
  Abboud\[[@pone.0207088.ref047]\]        2007   38        269             9                            54               3                        13    \-   \-    13   90
  Irkorucu\[[@pone.0207088.ref051]\]      2007   10        263             2                            13               \-                       \-    \-   \-    \-   \-
  Sippel\[[@pone.0207088.ref064]\]        2007   33        480             17                           120              3                        14    3    14    14   110
  Manouras\[[@pone.0207088.ref032]\]      2008   100       408             16                           66               \-                       \-    \-   ---   \-   \-
  Erbil\[[@pone.0207088.ref050]\]         2009   48        392             \-                           \-               \-                       \-    \-   \-    14   97
  Rajinikanth\[[@pone.0207088.ref060]\]   2009   47        317             30                           120              13                       41    \-   \-    \-   \-
  Sorgato\[[@pone.0207088.ref008]\]       2009   70        812             37                           203              28                       141   \-   \-    64   610
  Turanli\[[@pone.0207088.ref066]\]       2009   25        392             \-                           \-               \-                       \-    14   92    \-   \-
  Ondik\[[@pone.0207088.ref056]\]         2010   13        29              \-                           \-               5                        21    \-   \-    \-   \-
  Spiliotis\[[@pone.0207088.ref003]\]     2010   32        283             14                           21               \-                       \-    \-   \-    18   83
  Youssef\[[@pone.0207088.ref009]\]       2010   26        181             9                            26               \-                       \-    \-   \-    16   108
  Khairy\[[@pone.0207088.ref010]\]        2011   47        240             19                           104              2                        15    \-   \-    30   61
  Qasaimeh\[[@pone.0207088.ref059]\]      2011   20        213             6                            16               \-                       \-    \-   \-    8    97
  Prazenica\[[@pone.0207088.ref017]\]     2014   58        1010            7                            96               7                        64    \-   \-    52   704
  Song\[[@pone.0207088.ref065]\]          2014   90        364             \-                           \-               86                       246   \-   \-    \-   \-
  Applewhite\[[@pone.0207088.ref048]\]    2016   283       271             197                          158              80                       20    \-   \-    \-   \-
  Manatakis\[[@pone.0207088.ref011]\]     2016   70        211             23                           63               \-                       \-    \-   \-    \-   \-
  Zhou\[[@pone.0207088.ref018]\]          2016   78        308             37                           43               25                       15    4    21    56   185
  Lin\[[@pone.0207088.ref004]\]           2017   204       2982            80                           540              40                       73    28   255   89   567

Abbreviation: IP incidental thyroidectomy.

Publication bias, sensitivity analysis and heterogeneity assessment {#sec012}
-------------------------------------------------------------------

Begg's and Egger's test were conducted to assess publication bias in this meta-analysis. In the risk factor analysis, all tests found no significance for malignancy, central neck dissection, or total thyroidectomy. For the analysis of reoperation, the number of studies was too small to conduct Begg's or Egger's test. None of the tests showed significance for temporary/permanent postoperative hypocalcemia (Begg's p = 0.4769 and Egger's p = 0.253) or permanent hypocalcemia (Begg's p = 0.6534 and Egger's p = 0.1139). The funnel plot of temporary/permanent postoperative hypocalcemia and permanent hypocalcemia was somewhat asymmetric, indicating some publication bias in the analysis. ([S1](#pone.0207088.s001){ref-type="supplementary-material"} and [S2](#pone.0207088.s002){ref-type="supplementary-material"} Figs) The meta-analysis was recalculated after omitting every record included in the analysis to check the sensitivity of our overall results. As shown in [S3](#pone.0207088.s003){ref-type="supplementary-material"} and [S4](#pone.0207088.s004){ref-type="supplementary-material"} Figs, the results for temporary/permanent and permanent hypocalcemia were robust after omitting each of the records in turn. Three variables were included in the meta-regression analysis; continent, year of study and NOS. We found that all three factors did not have any impact on the findings and did not explain the observed heterogeneity in the analysis. Only the continent of Europe might partly explain the heterogeneity found for permanent hypocalcemia, having a p value of 0.0898. ([S3 Table](#pone.0207088.s008){ref-type="supplementary-material"}) Further analysis of European studies found no significant effect for permanent hypocalcemia (RD = 0.0058; 95% CI: -0.0121 to 0.0236; p = 0.5261). Another analysis of non-European articles showed that IP had a significant effect on permanent hypocalcemia (RD = 0.0307; 95%CI: 0.0116 to 0.0497; p = 0.0016).

Pathology results {#sec013}
-----------------

Detailed pathology data are listed in [S4 Table](#pone.0207088.s009){ref-type="supplementary-material"}. Only one parathyroid gland was incidentally excised in the majority of IP cases, while two or more parathyroid glands were found postoperatively in the remaining 6.4--20.0% of cases. The location of parathyroid gland in the specimens was diverse. In total, 2.2--50.0% of parathyroid glands were identified in an intrathyroidal location, 16.7--40.0% were identified in an intracapsular location, and 15.7--81.1% were identified in an extracapsular location. ([S4 Table](#pone.0207088.s009){ref-type="supplementary-material"})

Risk factors of IP {#sec014}
------------------

To identify the risk factors of IP, we collected IP incidence data by examining factors such as malignancy, central neck dissection, total thyroidectomy and reoperation. ([Table 3](#pone.0207088.t003){ref-type="table"}) The risk of IP in thyroidectomy was significantly higher for malignancy cases (RR = 1.60; 95% CI: 1.27 to 2.02; p\< 0.0001). Central neck dissection was found to be associated with higher risk of IP in thyroidectomy (RR = 2.35; 95% CI: 1.47 to 3.75; p = 0.0004). The rate of total thyroidectomy in IP (57.2%) was obviously higher than that in non-IP (38.0%) cases. Four studies reported data on reoperation rate. Meta-analysis of these data showed that reoperation influenced the incidence of IP in thyroidectomy (RR = 1.81; 95% CI: 1.20 to 2.75; p\<0.005).

10.1371/journal.pone.0207088.t003

###### Risk factors of IP.
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  Risk factors              IP, n   Non-IP, n   RR \[95% CI\]   p value   Number of studies                 
  ------------------------- ------- ----------- --------------- --------- --------------------- ----------- ----
  Malignancy                528     1233        1810            8745      1.60 \[1.27; 2.02\]   \< 0.0001   18
  Central neck dissection   297     982         673             7202      2.35 \[1.47; 3.75\]   0.0004      12
  Total thyroidectomy       386     675         2769            7290      1.42 \[1.20; 1.67\]   \< 0.0001   12
  Reoperation               49      340         382             4162      1.81 \[1.20; 2.75\]   0.005       4

Abbreviation: IP, incidental thyroidectomy; RR, risk ratio; CI, confidence interval.

Temporary/permanent postoperative hypocalcemia {#sec015}
----------------------------------------------

Temporary/permanent postoperative hypocalcemia data were available in 28 studies after excluding studies without a clear hypocalcemia definition. When calculating the overall effect, we pooled all data regardless of whether the hypocalcemia was biochemical or clinical. For 8 studies containing both biochemical and clinical hypocalcemia, we preferentially selected biochemical hypocalcemia for the overall effect analysis. The overall analysis found a significantly higher risk of temporary/permanent postoperative hypocalcemia in IP cases ([Fig 2](#pone.0207088.g002){ref-type="fig"}), with an RR of 1.59 (95% CI: 1.37 to 1.84; p\< 0.0001). Subgroup analysis was performed according to factors of concern ([Table 4](#pone.0207088.t004){ref-type="table"}). An analysis only including biochemical hypocalcemia showed that IP was associated with a higher risk of postoperative hypocalcemia (RR = 1.70; 95% CI: 1.45 to 1.99; p\< 0.0001). Fourteen studies reported data on clinical hypocalcemia. Further subgroup analysis found that IP increased the risk of clinical hypocalcemia in thyroidectomy with an RR of 1.54 (95% CI: 1.22 to 1.94; p = 0.0003). To study the influence of IP incidence on hypocalcemia, we divided all data into two groups according to the average IP incidence of 12.4% (\>12.4% and \< = 12.4%). The analysis showed a significant result in both groups. Total thyroidectomy and malignancy were found to be high risk factors of IP. A specific analysis of cases undergoing total thyroidectomy confirmed the influence of IP on temporary/permanent postoperative hypocalcemia. Data on malignancy were reported in only 5 studies. A comparable incidence of temporary/permanent hypocalcemia was identified between IP and non-IP cases.

![Forest plot of temporary/permanent postoperative hypocalcaemia.](pone.0207088.g002){#pone.0207088.g002}

10.1371/journal.pone.0207088.t004

###### Subgroup analysis of hypocalcaemia type, permanent definition, IP incidence, total thyroidectomy and malignancy.
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  Subgroups                                                   IP, n                     Non-IP, n   RR \[95% CI\] or RD \[95% CI\]   p value   Number of studies                                            
  ----------------------------------------------------------- ------------------------- ----------- -------------------------------- --------- ------------------- ---------------------------- ----------- ----
  Temporary/permanent hypocalcemia, hypocalcaemia type                                                                                                                                                      
                                                              Biochemical               495         1305                             1860      9625                1.67 \[1.43; 1.96\]          \< 0.0001   22
                                                              Clinical                  154         806                              494       3396                1.54 \[1.22; 1.94\]          0.0003      14
  Permanent hypocalcaemia, duration of permanent definition                                                                                                                                                 
                                                              6 months                  45          672                              142       6556                0.0243 \[0.0001; 0.0486\]    0.0495      13
                                                              ≥12 months                35          605                              76        4089                0.0200 \[0.0007; 0.0393\]    0.0422      10
  Incidence of IP \< 12%                                                                                                                                                                                    
                                                              Total hypocalcaemia       197         577                              1493      7859                1.79 \[1.36; 2.36\]          \< 0.0001   13
                                                              Permanent hypocalcaemia   35          503                              163       7750                0.0163 \[-0.0122; 0.0449\]   0.2626      11
  Incidence of IP ≥ 12%                                                                                                                                                                                     
                                                              Total hypocalcaemia       387         1021                             758       3395                1.51 \[1.36; 1.66\]          \< 0.0001   15
                                                              Permanent hypocalcaemia   45          774                              55        2895                0.024 \[0.0075; 0.0405\]     0.0044      12
  Total thyroidectomy                                                                                                                                                                                       
                                                              Total hypocalcaemia       311         769                              753       3033                1.45 \[1.17; 1.80\]          0.0007      10
                                                              Permanent hypocalcaemia   34          590                              50        3561                0.0201 \[0.0006; 0.0397\]    0.0429      10
  Malignancy                                                                                                                                                                                                
                                                              Total hypocalcaemia       98          272                              293       946                 1.16 \[0.84; 1.60\]          0.3628      5
                                                              Permanent hypocalcaemia   32          329                              54        1285                3.10 \[2.01; 4.78\]          \< 0.0001   5

Abbreviation: IP incidental thyroidectomy; RR, risk ratio; RD, risk difference; CI, confidence interval.

Permanent hypocalcemia {#sec016}
----------------------

Due to the low incidence of permanent hypocalcemia, the number of events in several studies was zero for both IP and non-IP. We introduced RD to identify the difference between two groups in accordance with the recommendations of the Cochrane Collaboration. As shown in [Fig 3](#pone.0207088.g003){ref-type="fig"}, the overall analysis of 23 studies found that IP was significantly associated with permanent hypocalcemia (RD = 0.0220; 95% CI: 0.0069 to 0.0370; p = 0.0042). Considering the different definitions of permanent hypocalcemia, we performed separate analyses of cases with definitions of permanent hypocalcemia as being 6 months or longer than 12 months ([Table 3](#pone.0207088.t003){ref-type="table"}). For studies in which the definition was 6 months, the incidence of permanent hypocalcemia in IP (6.7%) was much higher than that in non-IP (2.2%) cases, with an RD of 0.0243 (95% CI: 0.0001 to 0.0486; p = 0.0495). For studies in which the definition of permanent hypocalcemia was hypocalcemia lasting longer than 12 months, the influence of IP on permanent hypocalcemia was confirmed (p = 0.0422). A significant association was found between IP and permanent hypocalcemia in studies with an IP incidence \>12.4% but not in studies with an IP incidence of 12.4% or lower. Subgroup analysis of high risk factors found a significant effect of IP on permanent hypocalcemia in total thyroidectomy (RD = 0.0201; 95% CI: 0.0006 to 0.0397; p = 0.0429) and malignancy (RR = 3.10; 95% CI: 2.01 to 4.78; p\<0.0001) cases.

![Forest plot of permanent postoperative hypocalcaemia.](pone.0207088.g003){#pone.0207088.g003}

Discussion {#sec017}
==========

Incidental parathyroidectomy can occur in any operation on the thyroid, even in experienced surgeons' hands. According to the articles included in our review, the incidence of IP in thyroidectomy ranged from 2.9% to 31.0%. Among the incidentally excised parathyroid glands, 2.2--50.0% were identified as intrathyroidal postoperatively, indicating that the complete elimination of IP is almost impossible. However, more meticulous intraoperative identification of the parathyroid gland might reduce the incidence of IP because 16.7--40.0% of the incidentally excised parathyroid glands were found in an intracapsular location and 15.7--81.1% were found in an extracapsular location.

Much effort has been expended to identify the risk factors of IP in thyroidectomy. Lin et al. conducted a retrospective cohort study of 3,186 thyroidectomy cases and reported an IP incidence of 6.4%.\[[@pone.0207088.ref004]\] An analysis of this large set of sample data showed that malignancy, total thyroidectomy, central neck dissection and reoperation influence the incidence of IP. However, a comparable rate of IP was observed in malignant and benign cases by several researchers.\[[@pone.0207088.ref010], [@pone.0207088.ref011], [@pone.0207088.ref054], [@pone.0207088.ref062]\] We pooled these data and confirmed that malignancy is a risk factor for IP. Malignant lesions might invade the parathyroid gland along with adjacent tissue adhesions. There is a wider extent of operation in total thyroidectomy, and this increases the risk of incidental IP. The results of our meta-analysis support this hypothesis. Controversial results have been obtained concerning the effect of central neck dissection and reoperation on IP incidence.\[[@pone.0207088.ref004], [@pone.0207088.ref010], [@pone.0207088.ref054]\] Our meta-analysis showed that central neck dissection and reoperation significantly influence the incidence of IP.

Naturally, parathyroidectomy was considered to influence the function of parathyroid gland, regardless of whether the parathyroidectomy was intentional or incidental. Hence, the effect of IP on postoperative hypocalcemia in thyroidectomy has attracted much attention. An increased incidence of temporary/permanent postoperative hypocalcemia and permanent hypocalcemia in IP cases was confirmed by a high volume center experience.\[[@pone.0207088.ref004]\] However, Prazenica et al. reviewed 1,068 thyroidectomy cases and found that IP in thyroidectomy was associated only with temporary/permanent postoperative hypocalcemia and not with permanent hypocalcemia.\[[@pone.0207088.ref017]\] Debate continued on the association between IP and postoperative hypocalcemia.\[[@pone.0207088.ref011], [@pone.0207088.ref012], [@pone.0207088.ref014], [@pone.0207088.ref065]\] We performed a comprehensive review of the literature and meta-analysis of the results. A significant relationship was observed between IP and postoperative hypocalcemia regardless of whether the hypocalcemia was temporary/permanent or permanent.

The definitions of temporary/permanent and permanent postoperative hypocalcemia, the incidence of IP in thyroidectomy, the extent of the procedure and the final pathologic diagnoses varied, possibly accounting for the difference in the results obtained when studying this topic; thus, a further subgroup analysis was conducted. There were two different definitions of temporary/permanent postoperative hypocalcemia: a biochemical definition and a clinical definition. Although these two definitions partially overlap, the incidence of clinical hypocalcemia (4--39%) was lower than that of biochemical hypocalcemia (3--56%). \[[@pone.0207088.ref009], [@pone.0207088.ref015], [@pone.0207088.ref048], [@pone.0207088.ref053], [@pone.0207088.ref054], [@pone.0207088.ref065]\] In our study, IP was found to be associated with an increased incidence of temporary/permanent hypocalcemia, regardless of whether the biochemical or clinical definition was used. Kihara et al. followed 99 thyroidectomy cases with a detailed measure of hypocalcemia and found that serum calcium levels returned to stability after 6 months postoperatively, indicating that a definition of permanent hypocalcemia based on 6 months was suitable.\[[@pone.0207088.ref068]\] In accordance with this, our results found that IP cases increased the risk of permanent hypocalcemia as defined based on 6 months and more than 12 months. The overall incidence of IP in all the included studies was 12%. According to the overall IP incidence, studies were divided into high or low IP incidence groups. For the high IP incidence group, IP was associated with both temporary/permanent and permanent hypocalcemia. However, in the low IP incidence group, IP increased only the risk of temporary/permanent hypocalcemia and did not increase the risk of permanent hypocalcemia. As mentioned above, high IP incidence might be associated with some high-risk factors, such as a large extent of the procedure and a malignant pathologic diagnosis. Further analysis of temporary/permanent thyroidectomy cases found that IP influenced both temporary/permanent and permanent postoperative hypocalcemia. For malignant cases, IP increased only permanent hypocalcemia and did not increase temporary/permanent hypocalcemia. However, the majority of the 5 studies focusing on malignant cases were clinical hypocalcemia, and this should be kept in mind when interpreting this result.

There were several limitations in our study. First, the definition of permanent hypocalcemia varied between the included studies. Although we conducted subgroup analyses of different follow-up durations, the effect of other definitions, including continued calcium supplementation and serum calcium and serum parathormone levels, was not discussed due to insufficient sample size. Second, confounders and heterogeneity remained in our analysis. Surgery volume might also be a confounder in this topic because experienced high-volume surgeons might dissect more expertly and have greater anatomical knowledge of the parathyroid gland. In addition, thyroid pathology experts at higher-volume centers might be better at identifying IPs. However, few studies included relevant data. Some study included cases that received intraoperative parathyroid gland transplantation, and this a known factor affecting postoperative hypocalcemia. The influence of lymph node dissection and reoperation could also not be eliminated because is no recognized standard for reporting this topic. Some low-quality studies did not report data in a standardized fashion, which might also have caused the heterogeneity and publication bias found in our analysis. Further multicenter research might be necessary to address this issue. Sensitivity analysis, subgroup analysis, and a random-effects model were used to address this. The interpretation of our results should be based on a sufficient understanding of these limitations.

Conclusion {#sec018}
==========

This meta-analysis indicates that malignancy, central neck dissection, total thyroidectomy and reoperation are significant risk factors of IP. IP was found to increase the incidence of temporary/permanent and permanent postoperative hypocalcemia. We recommend more meticulous intraoperative identification of the parathyroid gland in thyroidectomy to reduce IP, particularly for total thyroidectomy and malignant cases. This study confirms the effect of IP on postoperative hypocalcemia and suggests that a new technique to help reduce IP is necessary.
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